In 2022, we discovered a new class of neoantigens derived from human endogenous retroviruses (HERVs) in breast cancer, revealing an untapped therapeutic target space for next-generation precision immunotherapy.
Discovery of HERV-Derived Neoantigens for Breast Cancer Immunotherapy
In 2022, Qing Wang and collaborators identified a new category of tumor neoantigens derived from human endogenous retroviruses (HERVs), revealing an unexpected source of immunotherapy targets in breast cancer. The discovery was enabled by the Valid-NEO® platform, a targeted proteomics technology developed to experimentally detect and validate neoantigen peptides directly from biological samples.
Human endogenous retroviruses are ancient viral sequences embedded in the human genome as a result of infections that occurred millions of years ago. Although most of these viral elements remain silent in normal tissues, certain cancers can reactivate them, producing viral-like proteins that are not normally present in healthy adult cells.
Using the Valid-NEO® neoantigen validation approach, Wang’s team was able to directly detect peptides derived from these reactivated viral elements and confirm that they can be presented as tumor-specific neoantigens.
Expanding the Landscape of Cancer Neoantigens
Before this discovery, most neoantigen research focused primarily on peptides generated by somatic mutations in cancer driver genes. While these mutation-derived peptides remain important therapeutic targets, the identification of HERV-derived neoantigens revealed that tumors may expose additional immunogenic signals originating from reactivated viral sequences within the human genome.
Because these viral-derived peptides are typically absent in normal tissues, they represent a highly attractive class of tumor-specific antigens that may be targeted by immune-based therapies.
This work therefore introduced an entirely new category of neoantigen resource for cancer immunotherapy.
The Role of the Valid-NEO® Platform
The identification of HERV-derived neoantigens was made possible through the Valid-NEO® platform, which integrates genomic information with ultra-sensitive targeted proteomics methods to experimentally validate neoantigen peptides.
Unlike prediction-based approaches that rely solely on DNA sequencing and computational modeling, Valid-NEO® enables direct detection and quantitative confirmation of candidate neoantigens, allowing researchers to determine whether predicted targets are truly produced and presented by tumor cells.
By applying this technology, Wang’s team was able to uncover neoantigen peptides originating from endogenous retroviral elements that had previously been difficult to identify using conventional methods.
Enabling New Strategies for Precision Immunotherapy
The discovery of HERV-derived neoantigens expands the range of molecular targets available for next-generation cancer immunotherapies. These targets may support the development of:
- neoantigen-directed T-cell therapies
- bispecific antibody strategies
- personalized cancer vaccines
- immune therapies targeting viral-like tumor antigens
More broadly, this work illustrates how systematic molecular measurement technologies can reveal previously hidden layers of cancer biology.
From Neoantigen Discovery to Platform Medicine
For Complete Omics, the discovery of HERV-derived neoantigens reinforces the broader vision that comprehensive molecular measurement can unlock entirely new classes of therapeutic targets.
Technologies such as Valid-NEO® and the Complete360® ultra-deep clinical proteomics platform are designed to enable large-scale detection of disease-associated peptides and proteins across human cancers.
By expanding the measurable molecular landscape of tumors, these platforms aim to support the discovery of new biomarkers, drug targets, and immunotherapy strategies across a wide range of diseases.
At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. Lorem ipsum dolor sit amet, consetetur sadipscing elitr.